These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 36579950)

  • 21. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereochemistry Enhances Potency, Efficacy, and Durability of
    Byrne M; Vathipadiekal V; Apponi L; Iwamoto N; Kandasamy P; Longo K; Liu F; Looby R; Norwood L; Shah A; Shelke JD; Shivalila C; Yang H; Yin Y; Guo L; Bowman K; Vargeese C
    Transl Vis Sci Technol; 2021 Jan; 10(1):23. PubMed ID: 33510962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.
    Engelhardt JA; Fant P; Guionaud S; Henry SP; Leach MW; Louden C; Scicchitano MS; Weaver JL; Zabka TS; Frazier KS;
    Toxicol Pathol; 2015 Oct; 43(7):935-44. PubMed ID: 25717082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery is key: lessons learnt from developing splice-switching antisense therapies.
    Godfrey C; Desviat LR; Smedsrød B; Piétri-Rouxel F; Denti MA; Disterer P; Lorain S; Nogales-Gadea G; Sardone V; Anwar R; El Andaloussi S; Lehto T; Khoo B; Brolin C; van Roon-Mom WM; Goyenvalle A; Aartsma-Rus A; Arechavala-Gomeza V
    EMBO Mol Med; 2017 May; 9(5):545-557. PubMed ID: 28289078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense comes of age.
    Flanagan WM
    Cancer Metastasis Rev; 1998 Jun; 17(2):169-76. PubMed ID: 9770113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.
    Tessier Y; Achanzar W; Mihalcik L; Amuzie C; Andersson P; Parry JD; Moggs J; Whiteley LO
    Nucleic Acid Ther; 2021 Feb; 31(1):7-20. PubMed ID: 33054599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meeting report: oligonucleotide ADME workshop.
    Hood S; Kenworthy D; Christensen JK
    Xenobiotica; 2022 Aug; 52(8):957-961. PubMed ID: 36093882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics.
    Cavagnaro J; Berman C; Kornbrust D; White T; Campion S; Henry S
    Nucleic Acid Ther; 2014 Oct; 24(5):313-25. PubMed ID: 25137397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense Oligonucleotide (AS-ODN) Technology: Principle, Mechanism and Challenges.
    Gheibi-Hayat SM; Jamialahmadi K
    Biotechnol Appl Biochem; 2021 Oct; 68(5):1086-1094. PubMed ID: 32964539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of delivery systems to improve target efficacy of oligonucleotides.
    Shoji Y; Nakashima H
    Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2-A Key Single Gene Target for Safe and Effective Inhibition of TGFβ Signaling.
    Kuespert S; Heydn R; Peters S; Wirkert E; Meyer AL; Siebörger M; Johannesen S; Aigner L; Bogdahn U; Bruun TH
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia.
    Stone LS; Vulchanova L
    Adv Drug Deliv Rev; 2003 Aug; 55(8):1081-112. PubMed ID: 12935946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of Antisense RNA Therapeutics: Turning Negative Results Into a Positive Development.
    Eilers W; Denti MA
    Nucleic Acid Ther; 2021 Jun; 31(3):183-184. PubMed ID: 34097476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes.
    Miyano-Kurosaki N; Barnor JS; Takeuchi H; Owada T; Nakashima H; Yamamoto N; Matsuzaki T; Shimada F; Takaku H
    Antivir Chem Chemother; 2004 Mar; 15(2):93-100. PubMed ID: 15185727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.